Protocol Single compound
Tirzepatide
GIP / GLP-1 dual agonist
Dual GIP and GLP-1 receptor agonist studied in large clinical trials for glycemic control and weight reduction.
Compare side by side →Compared with:Retatrutide vs TirzepatideSemaglutide vs Tirzepatide
Protocol card · research reference
- Starting dose
- 2.5 mg
- Studied range
- 2.5–15 mg
- Frequency
- Once weekly
- Route
- Subcutaneous
- Cycle
- Ongoing, titrated every 4 weeks
Titration schedule
- 01Weeks 1–42.5 mg
- 02Weeks 5–85 mg
- 03Weeks 9–127.5 mg
- 04Weeks 13–1610 mg
- 05Weeks 17–2012.5 mg
- 06Weeks 21+15 mg (max studied)
Reconstitution reference
Storage: Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
Tirzepatide
Once weekly · units to draw on a U-100 syringe for a 2.5 mg dose.
| Vial | BAC water | mg/mL | Draw | Doses |
|---|---|---|---|---|
| 10 mg | 1 mL | 10 | 25 u | 4 |
| 10 mg | 2 mL | 5 | 50 u | 4 |
| 10 mg | 3 mL | 3.33 | 75 u | 4 |
| 15 mg | 1 mL | 15 | 16.7 u | 6 |
| 15 mg | 2 mL | 7.5 | 33.3 u | 6 |
| 15 mg | 3 mL | 5 | 50 u | 6 |
| 30 mg | 1 mL | 30 | 8.3 u | 12 |
| 30 mg | 2 mL | 15 | 16.7 u | 12 |
| 30 mg | 3 mL | 10 | 25 u | 12 |
Notes
- Increase only if the current step is tolerated; GI effects are the most reported.
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Research dossier · published literature summary
01
Mechanism of action
Tirzepatide is a single peptide that activates both the GIP and GLP-1 receptors (a 'twincretin'). It carries a fatty-acid chain for albumin binding and once-weekly exposure. Combined GIP/GLP-1 signalling affects insulin and glucagon secretion, gastric emptying and appetite.
02
Observed research endpoints
- SURMOUNT-1 (obesity, no diabetes): mean weight change of −15.0% to −20.9% across dose arms vs −3.1% with placebo at week 72.
- SURPASS-2 (type 2 diabetes): every tirzepatide arm lowered HbA1c more than semaglutide (−2.01 to −2.30 vs −1.86 points).
- SURMOUNT-5 (head-to-head, obesity): −20.2% weight change vs −13.7% with semaglutide at week 72.
03
Regulatory & safety context
- FDA-approved (as Mounjaro and Zepbound) for specific indications; research-grade material is not an approved product.
- Gastrointestinal events were the most common adverse effects and occurred mostly during dose escalation.
04
Citations
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.2022-07Phase 3 randomized controlled trialRead paper ↗
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503–515.2021-08Phase 3 head-to-head RCTRead paper ↗
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26–36.2025-07Phase 3b head-to-head RCTRead paper ↗
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
Supplier C
TBDPlaceholder — details coming soon